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iscussion
r John D. Mitchell (Denver, Colo). This study details your
nstitution’s experience with PET and subsequently PET/CT for
taging the mediastinum in the setting of NSCLC. Using integrated
ET/CT, you found improved sensitivity but reduced specificity in
etecting N2 disease. The negative predictive value remained high,
reater than 95%, and the overall accuracy of the imaging test
eclined somewhat with PET/CT to 82%. On the basis of the
ncreased false positive rate you saw with PET/CT, you advocate
or the continued need for mediastinoscopy to best stage the
ediastinal extent of disease. I agree with the ongoing need for
urgical staging in the mediastinum, and I have a few questions for
ou.
First, we have had some issues at our institution with our
uclear medicine physicians interpreting the CT part of the PET/
T. In your manuscript you report that dedicated nuclear medicine
olleagues read these studies. Do you believe that they have
dequate body imaging experience or have you seen similar prob-
ems at your institution? Could this account for some of the
hanges you saw between PET and PET/CT?
Dr Lee. I agree and this is actually a good point that was
rought up during our morning session. We have two centers
hat do the vast majority, greater than 95%, of our integrated
ET/CT imaging at our institution, and each center essentially
as dedicated physicians specialized in nuclear medicine read-
ng who are also specialized in body chest CT reading. At our
nstitution we do not have that detriment of a lack of expertise
n CT imaging. However, since the CT images acquired during
ET/CT are without contrast, any radiologist will have a more
ifficult time comparing those images versus a contrasted CT
can. However, most of these patients also have a previous
ontrasted CT scan, which also is used during the time of the
eading.
Dr Mitchell. Second, what constitutes a positive study at your
nstitution? In your manuscript you described a study as positive if
he degree of activity was “definitely above the surrounding me-
iastinum.” Do you use a specific SUV as a cutoff for a positive
tudy? It is going to have a tremendous effect on the sensitivity and
pecificity of the test.
Dr Lee. That is a good question that was actually discussed
his morning. At our institution, our radiologists typically will
ssign an SUV to our primary tumors but have not yet accepted
he practice of assigning SUVs to lymph nodes. It is our
ommon practice to use background uptake as a baseline level
nd designate as “positive” anything with increased SUV com-
ared with background. Because of this we probably were able
The Journal of Thoracico have an increased sensitivity. Likewise, because of this, the
pecificity is much lower, which leads to increased false posi-
ive results.
Dr Mitchell. On the basis of your results, have you thought
bout reinterpreting your data that would adjust your sensitivity
nd specificity based on the SUV value?
Dr Lee. That is something that we will probably want to go
ack and look at. Then if we can stratify on the basis of SUV we
ight be able to see exactly whether there is a cutoff. Dr Cerfolio
as identified around 5.2 as being that magic number at his
nstitution, and I know there is some variance from institution to
nstitution as well. I think that is something that we definitely will
ook forward to looking into.
Dr Mitchell. Next, the negative predictive value in your
tudy remains high, greater than 95%, with integrated PET/CT.
n the basis of your results, what do you advocate in terms of
urgical staging in the mediastinum if the PET/CT results are
egative?
Dr Lee. If the patient has a peripheral lesion that patients
hould be assumed to have, and if the PET/CT results are negative,
atients should be assumed to have a normal mediastinum and
hould proceed to direct thoracotomy and resection. Patients with
entral tumors, evidence of N1 disease, should be more closely
valuated with mediastinoscopy first. If the patients have large
ulky central lesions that may require pneumonectomy, it is to
heir benefit to clearly identify or rule them out from having
ediastinal disease before pneumonectomy.
Dr Mitchell. Finally, others have reported increased accuracy
n staging the mediastinum, as you alluded to, using an integrated
ET/CT, but your data suggest otherwise. How do you account for
he differences in the studies?
Dr Lee. We also touched on this a little bit. It has to do with
ow you assign what is a positive integrated PET/CT. If the
UV or if your way of identifying or calling a positive study is
et too low, you will have a higher number of false positive
esults. There has also been evidence that geographic differ-
nces exist. In our part of the country, we actually have a much
igher incidence of both sarcoid disease and histoplasmosis.
hat may play into the fact that we had a much higher incidence
f false positive results.
Dr Robert Cerfolio (Birmingham, Ala). First of all, con-
ratulations on your fine work. I encourage you to do these
ypes of studies and I invite you to add the max-SUV and cutoff
alues because they will completely change your data and your
esults—whether the node is positive or not. I think you need to
et the bar for the max-SUV of the lymph node and objectively
all it positive or negative and then prove whether you are right
r wrong. Although your study and our study have somewhat
ifferent conclusions, I do not think they are all that different.
hat I was hoping to see was a specific T and an N and a
pecific nodal station analysis, as we have described in several
apers. Was that included in your manuscript but left out of
our presentation for lack of time, or was that not done?
Dr Lee. That actually was not done. The reason is that our nuclear
edicine readouts are not assigned to say we have an R4 node that is
ositive. They will typically just say the mediastinum is positive.
Dr Cerfolio. I think if you are going to look at the accuracy of
and Cardiovascular Surgery ● Volume 133, Number 3 751
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TShe TNM, you have to look at the accuracy for each nodal station.
sk the nuclear radiologists what the T is and what the N is and
hich N is positive to see if they are right.
Dr Lee. I totally agree. It may be that we will have to change
ur practice at our institution to start doing that.
DOCTOR. I would encourage you to take this to the pulmonol-52 The Journal of Thoracic and Cardiovascular Surgery ● Marcgy meetings, to the medical oncology and radiation oncology
eetings, because they are reading those tests. They are bypassing
ou and are treating these patients as if they have advanced
isease. The specificity question is vital, and I would strongly
ncourage you to take this information to these people. Tissue is
he issue, and we have to tell them that.h 2007
